South Korean solar inverter makers have jointly launched a new association of inverter manufacturers to coordinate domestic production, safeguard local expertise, and address import-driven market ...
The new 12.5 kWh pack-based design supports flexible configuration up to 250 kWh per system. An optional long-duration combiner box supports 2–4 clusters, expandable to 1,000 kWh and 8 hours of ...
Zacks Investment Research on MSN
FDA Greenlights Novartis' Gene Replacement Treatment for SMA
Novartis NVS obtained FDA approval for onasemnogene abeparvovec-brve, a gene replacement therapy, for children two years and ...
The FDA has approved Itvisma (onasemnogene abeparvovec-brve) to treat children two years and older, teens, and adults living with spinal muscular atrophy (SMA). It is indicated for patients with a ...
Itvisma contains the active ingredient in Zolgensma approved in 2019 for children younger than 2 years but is reformulated ...
Onasemnogene abeparvovec-brve is the first gene replacement therapy approved for SMA patients aged 2 years and older, expanding access beyond infants. Phase 3 trials demonstrated significant motor ...
The global solar inverter market was valued at US$12.81 billion in 2023 and is forecasted to reach US$24.40 billion by 2029, with a CAGR of 11.34% from 2024-2029. Solar inverters are crucial for ...
9don MSNOpinion
Silver boom continues unabated – Take advantage of setbacks at Silver North Resources, First Majestic, and SMA!
In light of geopolitical tensions and real purchasing power losses, precious metal prices are on the rise – and there is no ...
Investing.com -- Jefferies upgraded German solar inverter manufacturer SMA Solar to “buy” from “hold” and raised its price target to €39 from €22, citing improved profitability prospects driven by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback